Back
38
Day Range
$75.25
$116.19
52-Week Range
$75.25
$116.19
Volume
800
50D / 200D Avg
$116.19
/
$93.07
Prev Close
$116.19
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 32.0 | 0.3 |
| P/B | 3.9 | 2.9 |
| ROE % | 12.0 | 3.7 |
| Net Margin % | 4.4 | 3.8 |
| Rev Growth 5Y % | 1.9 | 10.0 |
| D/E | 0.7 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$5.31
$5.19 – $5.39
|
5.1 B | 1 |
| FY2029 |
$4.83
$4.71 – $4.89
|
4.9 B | 1 |
| FY2028 |
$4.52
$4.41 – $4.58
|
4.7 B | 1 |
Key Takeaways
Revenue grew 1.92% annually over 5 years — modest growth
ROE of 11.95% — decent returns on equity
Generating 272.48M in free cash flow
P/E of 31.95 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3.60%
Cash machine — converts 150.39% of earnings into free cash flow
Growth
Revenue Growth (5Y)
1.92%
Revenue (1Y)5.52%
Earnings (1Y)-0.96%
FCF Growth (3Y)35.08%
Quality
Return on Equity
11.95%
ROIC6.57%
Net Margin4.38%
Op. Margin5.39%
Safety
Debt / Equity
0.72
Current Ratio1.15
Interest Coverage14.24
Valuation
P/E Ratio
31.95
P/B Ratio3.90
EV/EBITDA30.22
Dividend Yield0.03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 5.52% | Revenue Growth (3Y) | 5.10% |
| Earnings Growth (1Y) | -0.96% | Earnings Growth (3Y) | 2.16% |
| Revenue Growth (5Y) | 1.92% | Earnings Growth (5Y) | 1.96% |
| Profitability | |||
| Revenue (TTM) | 4.14B | Net Income (TTM) | 181.19M |
| ROE | 11.95% | ROA | 5.41% |
| Gross Margin | 10.37% | Operating Margin | 5.39% |
| Net Margin | 4.38% | Free Cash Flow (TTM) | 272.48M |
| ROIC | 6.57% | FCF Growth (3Y) | 35.08% |
| Safety | |||
| Debt / Equity | 0.72 | Current Ratio | 1.15 |
| Interest Coverage | 14.24 | Dividend Yield | 0.03% |
| Valuation | |||
| P/E Ratio | 31.95 | P/B Ratio | 3.90 |
| P/S Ratio | 1.40 | PEG Ratio | -23.26 |
| EV/EBITDA | 30.22 | Dividend Yield | 0.03% |
| Market Cap | 5.79B | Enterprise Value | 6.74B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.14B | 3.92B | 3.75B | 4.01B | 3.83B |
| Net Income | 181.19M | 182.95M | 173.60M | 165.13M | 167.68M |
| EPS (Diluted) | 3.63 | 3.67 | 5.72 | 3.32 | 3.38 |
| Gross Profit | 429.01M | 1.09B | 451.33M | 374.13M | 350.55M |
| Operating Income | 222.88M | 204.35M | 191.29M | 192.98M | 186.33M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 3.35B | 3.07B | 2.99B | 2.66B | 2.62B |
| Total Liabilities | 1.86B | 1.52B | 1.52B | 1.41B | 1.38B |
| Shareholders' Equity | 1.48B | 1.55B | 1.47B | 1.25B | 1.23B |
| Total Debt | 1.06B | 235.89M | 236.04M | 686.49M | 672.65M |
| Cash & Equivalents | 115.56M | 129.68M | 116.16M | 93.93M | 164.98M |
| Current Assets | 1.07B | 1.03B | 1.03B | 976.72M | 963.50M |
| Current Liabilities | 933.39M | 731.71M | 772.27M | 880.12M | 664.90M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#676 of 1052
Recent Activity
Entered
Cash Flow Compounder
Mar 25, 2026